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Abstract 
Objectives: To determine whether foot synovitis is associated with adverse radiographic and 
functional outcomes after 3 years in an inception rheumatoid arthritis (RA) cohort receiving 
treat-to-target combination DMARD therapy.  
Methods: Disease activity (DA) was assessed in early RA patients (n=266) using DAS28, 
clinical disease activity index (CDAI) and simplified disease activity index (SDAI). 
Radiographic outcomes were assessed with annual hand and feet radiographs and quality of 
life by SF-36. Prevalence of remission and foot synovitis was calculated using marginal 
binomial generalised estimating equations, transition between remission and non-remission 
states by a multi-state Markov model and changes in radiographic scores by a negative 
binomial mixed regression log-link model. Population matched SF-36 data were analysed by 
mixed-effects linear regression. 
Results: DA scores that omit foot joints were modest in their ability to capture foot synovitis. 
Despite relative stringency of SDAI and CDAI for remission, 25-36% of patients in remission 
had foot synovitis. In patients in remission, foot synovitis predicted transition from remission 
into relapse by up to 2-fold. Sustainability of remission markedly influenced progression of 
erosion scores (p=0.006). After adjusting for DA, foot synovitis was associated with worse 
SF-36 physical functioning (p=0.025). 
Conclusions: DA measures that omit foot joints capture foot synovitis poorly. When used to 
define remission, a substantial proportion have foot synovitis which predicts relapse and 
worse physical function. Foot synovitis influences sustainability of remission which in turn 
markedly influences radiographic progression. Regardless of remission status, persistent foot 
synovitis should prompt therapy escalation to improve long-term outcomes. 
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 Significance and Innovations: 
• Disease activity measures that omit foot joint assessment are modest in their ability to 
capture foot synovitis over time 
• The presence of foot synovitis in patients in remission predicts relapse into non-remission 
and worse radiographic and long-term functional outcomes 
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 4 
Rheumatoid arthritis (RA) is a systemic inflammatory disorder that can lead to progressive 
and irreversible joint damage. It is now well-established that intensive target-driven treatment 
with disease modifying anti-rheumatic drugs (DMARDs) produces substantial improvements 
in disease outcomes. These treatment strategies usually rely on a clinic-based composite 
disease activity (DA) measure and it follows that the ability of these measures to capture 
overall DA may influence disease outcomes.  
Various validated composite DA and remission measures have been utilised in published 
series. These include criteria that require a full joint count (e.g. the American College of 
Rheumatology (ACR) Boolean-based criteria) (1), and those employing abbreviated joint 
counts that omit assessment of the ankles and feet. The latter include the 28-joint count DA 
score (DAS28) (2), the Clinical Disease Activity Index (CDAI) and the Simplified Disease 
Activity Index (SDAI) (3). Of these, remission by SDAI has been adopted as an index based 
remission criteria in the recently proposed 2011 ACR/European League Against Rheumatism 
(EULAR) definition of remission (4).  
In an earlier cross-sectional study (5), we found that agreement between remission criteria is 
variable, with the best agreement between the CDAI and SDAI and the poorest with the 
DAS28 and other criteria. This makes comparison of treatments and outcomes among 
inception cohorts using different DA criteria more difficult.  
Furthermore, while abbreviated joint counts may simplify DA indices, we previously 
reported in the same cross-sectional study that DA measures that omit foot joints fail to 
capture synovitis in approximately one-third of patients. This is particularly relevant when it 
is considered that that the feet are the initial site of involvement in early RA in a third or 
more of patients (6), metatarsophalangeal (MTP) joint involvement is present at baseline in 
70% of patients with 40-50% still having painful MTPs after 2 years after diagnosis despite 
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treatment (7) and ~90% report painful ankles or feet at some point during the course of their 
disease (8). Therefore patients with active foot synovitis and well-controlled disease 
elsewhere may be at risk of ongoing damage if treatment decisions are made solely on the 
basis of these abbreviated DA measures (5).  
To explore if persistent foot synovitis should influence treatment, it is necessary to consider 
long-term disease outcomes. Radiographic progression is a robust longitudinal outcome 
measure (9) and foot joints exhibit erosive changes and joint space narrowing (JSN) more 
frequently at baseline and over time in comparison to hand joints in early RA (10). Therefore 
imaging provides a means of assessing whether failure to adjust treatments on the basis of 
persistent foot synovitis translates to different outcomes in the longer term. The 
multidimensional consequences of RA-related foot synovitis on function and health-related 
quality of life are best studied using patient-reported outcome measures. Of these, the health 
assessment questionnaire (HAQ) and the Medical Outcome Study Short-Form 36 (SF-36) are 
probably the best validated in RA. In addition, the SF-36 bodily pain and vitality subscales 
are the most responsive to improvement (11, 12).  
There are limited data regarding the radiographic and functional outcomes of foot synovitis. 
The objectives of this study were to investigate the long term radiographic and functional 
outcomes of foot synovitis at three years in intensively, predominantly conventional DMARD 
treated patients, with the treatment strategy aiming for remission. Our specific aims were (1) 
to investigate dynamic correlations (DCs) between DA measures and foot synovitis, (2) 
analyse the radiographic progression in patients with foot synovitis, and (3), to assess 
functional outcomes of foot synovitis over time.  
PATIENTS AND METHODS 
Participants 
Page 6 of 47
John Wiley & Sons, Inc.
Arthritis Care & Research
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review Only
Foot synovitis and radiographic and functional outcomes 
 
 
 6 
Our sample comprised consecutive adult (>18 years) patients with early (<12 months) RA 
presenting to the Early Arthritis Clinic (EAC) at the Royal Adelaide Hospital (RAH) between 
2000-2014. Inclusion criteria required participants to be DMARD-naïve and have RA 
according to the 1987 revised ACR (13) and/or the 2010 ACR/EULAR criteria (14). The 
study was approved by the RAH Human Research Ethics Committee.  
Study Protocol 
Details of the EAC cohort, treatment strategy, and results have been published elsewhere (15, 
16). Briefly, all patients commenced treatment with initial triple DMARD therapy 
(methotrexate 10mg weekly, sulfasalazine 500mg twice daily increased to 1g twice daily over 
3 weeks and hydroxychloroquine 200mg twice daily). Treatment was escalated to achieve 
DAS28(ESR) remission by increasing methotrexate to a maximum of 25mg weekly followed 
by addition of leflunomide, other DMARDs or a biologic DMARD according to a pre-
defined algorithm (15). If clinically deemed necessary, patients could have parenteral 
glucocorticoids (typically 120 mg IM depot methyl prednisolone); oral corticosteroids and 
NSAIDs were actively discouraged and if used at study entry, tapered and ceased where 
possible.  
Study evaluations and analyses 
Patients were reviewed every 3-6 weeks. Joint counts (JC) were assessed as tender (53 joints 
and 28 joints; TJC) and swollen (44 joints and 28 joints; SJC) joint counts; foot joints 
included the ankle and joints of the fore-, mid- and hind-foot. Foot synovitis was considered 
to be present if any of the aforementioned foot joints were tender and swollen. A 100 mm 
visual analogue scale was used to assess patient and physician global activity, pain and 
fatigue. Quality of life measures assessed included the modified health assessment 
questionnaire (mHAQ; every visit) and SF-36 (yearly).  
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Composite measures of DA assessed included the DAS28(ESR), DAS28(CRP), CDAI and 
SDAI. The DAS28 was calculated using 4 variables (TJC28, SJC28, general health, and 
ESR/CRP) (17); SDAI and CDAI were calculated using standard formulae (3). For these 
measures, remission was defined as a DAS28-ESR/CRP score of <2.6, CDAI score of ≤ 2.8 
or SDAI score of ≤ 3.3.(3, 18, 19) Patients had yearly radiographic assessments, which were 
scored using the Sharp modified van der Heijde (SvH) method (20) by two independent 
observers (SP, MW). Serial hand and feet radiographs were blinded to identity of participants 
but not to chronological order. 
Statistical analysis 
Statistical analysis was done using the R program for statistics (21). Dynamic (within patient) 
correlations between DA scores and foot TJC and SJC scores were estimated in patients with 
at least three treatment observations over three years’ of follow up (n=217; 810 observations) 
using the R library dynCorr (22), with 95% confidence intervals (CI) estimated by 
bootstrapping. The average prevalence (over all treatment visits) of (1) remission according 
to different DA criteria and (2) foot synovitis (defined as any tender or swollen joints) in 
patients in remission, was estimated using marginal binomial generalised estimating 
equations models in patients with at least one treatment visit (n = 266; 907 observations). 
Transitions between disease remission and non-remission states over time were analysed 
using a multi-state Markov model, using the R library msm (23) in patients with at least two 
treatment visits (n=263; 903 observations), and results are reported as the average length of 
stay (“sojourn time”) in either a remission or non-remission state for the different DA 
remission criteria. A second analysis included foot synovitis as a covariate and results are 
reported as hazard ratios for the effect of foot synovitis on the transition intensity for each 
transition direction. 
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 8 
Radiographic scores (n=238) over 3 years were analysed using a random intercept, marginal 
exponential growth model to calculate the average annual “growth” rate in scores. This was 
estimated using a negative binomial mixed regression model (log-link), rather than a Poisson 
regression model, because of overdispersion in the radiographic scores. This analysis was 
performed using the R library glmmADMB (24).   
For SF-36 data (n=255), each SF-36 domain scale (0-100) was transformed to a norm-based 
scale (NBS), with a mean of 50 (SD 10), using age and gender matched South Australian 
population data (25), to enable direct comparison between results of each domain. Mixed 
effects linear regression model was applied to analyse associations between disease activity 
and SF-36 scores over 3 years, using the R library nlme (26). To analyse the association of 
foot synovitis and SF-36 scores with foot synovitis as an additional predictor variable, foot 
joint scores were transformed with a square root transformation prior to analysis, because of 
the variable and skewed nature of foot joint counts.  
RESULTS 
Baseline patient characteristics 
The baseline characteristics of patients are presented in Table 1. The mean age was 55, 71% 
were women and 48% were current or past smokers. In this cohort, the prevalence of 
rheumatoid factor (RF), anti-CCP (cyclic citrullinated peptide) and the shared epitope was 
60%, 51% and 59% respectively. Mean baseline DAS28(ESR), SDAI and CDAI were 
consistent with high disease activity; mean mHAQ was 0.756 and mean duration of 
symptoms prior to diagnosis was 23 weeks. Baseline total (median) SvH score was 4; 27% of 
patients had erosive disease at baseline.  
DCs between DA scores and foot joint scores 
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 9 
Dynamic correlations (DCs; these were correlations of foot synovitis with DA within 
patients) were obtained from a minimum of 3 observations (from 6 months to 3 years) per 
patient, during treatment. The DCs within individuals over time are presented in Table 2. All 
DA scores showed a weak to moderate positive correlation with foot swollen joint counts 
(SJC) and tender joint counts (TJC) and the strength of these correlations improved when 
both SJC and TJC were considered. Correlations were comparable for 
DAS28(ESR)/DAS28(CRP) and SDAI/CDAI. Despite the statistical significance of these 
correlations, the DA scores ‘captured’ less than 50% of the variation in foot SJC/TJC counts, 
indicating that assessment of disease activity using these criteria is likely to be insufficient for 
detecting disease flares in the feet. Furthermore, even though the SDAI and CDAI are more 
stringent remission criteria as compared to the DAS28, 24% in SDAI remission and 25% of 
patients in CDAI remission had ongoing foot synovitis (Table 2). 
Sustainability of remission, foot synovitis and prediction of relapse  
As might be expected, we found that in the first 3 years, RA disease activity fluctuates with 
patients transitioning in both directions, between remission and non-remission. When we 
estimated the average length of stay in any one state (the “sojourn time”), we found that the 
sojourn time in remission for SDAI/CDAI was substantially shorter [1.0 years (95% CI 0.6, 
1.4) and 1.0 years (95% CI 0.7, 1.5) respectively] than that for DAS28 based remission [2.0 
years (95% CI 1.35, 2.7)].  
We included foot synovitis as a covariate to determine if the presence of foot synovitis 
affected the probability of transitioning from remission to non-remission, and found that foot 
synovitis significantly influenced the transition intensities (as assessed by the likelihood ratio 
p-value). Patients in DAS28(ESR), SDAI and CDAI remission with foot synovitis were 
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approximately twice as likely to relapse compared to patients in remission without foot 
synovitis (Table 3).  
Radiographic progression 
We analysed progression of both JSN and erosion scores over time. Because of the log-link 
employed in the regression model, the estimated average annual growth (i.e. increase) in 
scores represents the ratio of scores between successive yearly intervals, as opposed to the 
arithmetic difference in scores. The score “growth rate” is therefore strongly influenced by 
factors affecting the baseline score, and this was modelled appropriately in all analyses. 
Age was the most important predictor of baseline JSN, with higher scores occurring among 
older patients (p <0.001; data not shown). For baseline erosion scores, both baseline age and 
anti-CCP status were highly significant predictors (p <0.001). Indeed, results from our 
regression analysis revealed that the estimated ratio of erosion scores, at any given time point, 
for an anti-CCP positive patient as compared to an anti-CCP negative patient was 3.01 (95% 
CI 1.41, 6.84) i.e. a 3 fold difference. For patients with the same baseline age and anti-CCP 
status, the ratio of erosion scores at three years relative to their baseline score was estimated 
as 2.80 (95% CI 2.30, 3.41) i.e. nearly a 3 fold increase over three years. There were no 
significant associations (for either JSN or erosion scores after adjusting for age) with other 
baseline variables including gender, smoking status, duration of symptoms prior to treatment, 
BMI and baseline disease activity scores. 
The effect of sustained remission on the growth rate of erosion scores  
Regression analysis was performed by calculating a time dependant variable (“Time:DA 
remission.ave”; regression estimates are presented in Table 4) to measure whether DA 
remission was associated with the average annual growth rate of erosion scores. “Time:DA 
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remission.ave” reflects the proportion of times a patient was in DA remission over the 4 
treatment time points (6 months, 1 year, 2 years and 3 years).  Age was centred at the mean of 
55 years and the “contrast sum” contrasts [which uses contrast sum coding i.e. (-1,1) instead 
of dummy (0,1) coding] was used to dichotomise anti-CCP status. In this model, the “Time” 
coefficient reflects the (log) growth rate in erosion scores for patients who were never in 
remission; the “Time:DA.remission.ave” coefficient reflects the difference in the (log) 
growth rate for patients with varying success in achieving remission compared to those who 
never achieve remission. We found the coefficient here to be negative, and highly significant 
for each DA score, suggesting that the more remission is sustained, the more pronounced the 
benefit of remission in ameliorating the increase in erosion scores. This is particularly 
relevant, as the transition state analysis of the sojourn time presented earlier has shown that 
remission is more unstable in the presence of foot synovitis. 
Association of DA and foot synovitis with SF-36 scores  
Analysis of SF-36 scores (based on the baseline and mean score for each patient during 
treatment (years 1, 2 and 3) revealed that although mean SF-36 NBS improved with 
treatment, they were still lower than the general South Australian population scores (data not 
shown). Using regression analysis (data not shown), DA during treatment, as measured by the 
DAS28(CRP) was strongly associated with scores in each SF-36 domain, most pronounced 
for Physical Functioning (PF) and General Health (GH).  
We also analysed the relationship between foot synovitis (foot SJC and foot TJC) scores and 
each domain of the SF-36 during treatment, by the inclusion of an additional covariate (the 
square root of the total synovitis scores). As in the previous analysis, baseline age was 
centred around 55 years, and DAS28(CRP) was centred around 2.6 and the additional 
covariate for foot synovitis scores “sqrt.foot.SJC.TJC.c” was centered around √2. We found 
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that the foot joint score is quantitatively related to the SF-36 Physical Functioning (PF), NBS 
scale, even after adjustment for DAS28(CRP) (Table 5). The regression coefficient was 
negative, and highly significant for foot joint score, indicating a lower SF-36 PF in the 
presence of foot synovitis. The other SF-36 domain scores were associated with foot joint 
scores only if the DA score was omitted from the model, indicating that they are likely to be 
secondary associations induced by the correlation between foot joint scores and DA scores. 
DISCUSSION 
In this cohort of early RA, our study confirms and extends our previous findings concerning 
the underestimation of disease activity using DA measures that omit foot joints. When these 
criteria are used to define remission, a substantial proportion of patients have ongoing foot 
synovitis, which predicts relapse of standard DA measures, radiographic progression and 
worse functional outcomes.  
The goal of treatment in RA is achievement of remission, which is best regarded as a state at 
the very end of a continuum of diminishing disease activity. Given that no one single measure 
is adequate to define remission, composite measures introduced over the years have 
attempted to define cut-point values, with varying levels of stringency. Pinals’ statement in 
1981 that “substantial variation appears to exist in the concept of remission within the group 
of participating rheumatologists” (1, 4) still remains valid. In the current era of biologic 
DMARDs when remission is a realistic goal, it is critical not only to use stringent remission 
criteria, but also recognise their limitations, so that we may achieve the best long-term results 
in individuals. It is in this context that our study assumes particular relevance.  
There are limited longitudinal data on the ability of composite measures that use a limited 
joint count, to “capture” foot synovitis although it is recognised that the SDAI (27) and the 
original DAS (28) have greater stringency than the DAS28. For example, Landewe et al. 
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compared DAS with DAS28 remission using paired observations and found DAS remission 
to be more stringent than DAS28 remission, with the discrepancy accounted for by the 
omitted foot joints (28). Kapral et al. (29) compared remission using either a 28 joint count or 
a 32 joint count (this included the ankles and feet as a ‘block’ of 4 joints). Although they 
found that classification of disease activity remained similar whether 28 or 32-joint counts 
were used, DAS28 remission was frequently recorded in the presence of ankle/foot swelling 
(34%) and tenderness (31%). When SDAI remission was recorded, persistent ankle/foot 
swelling/tenderness occurred in only 8% of such patient visits. In contrast to our cohort, this 
last study had patients with longer disease duration at study entry (8 years mean disease 
duration) and lower baseline disease activity. Our patients had earlier, more active disease 
and this may account for the increase in persistent foot synovitis among our patients in 
remission despite intensive treat-to-target therapy.   
A study from an early RA inception cohort evaluating MTP synovitis found that up to 40% of 
patients in DAS28 remission had at least 1 MTP involved (30). Another study (31) from a 
different early RA cohort evaluated the new ACR/EULAR remission criteria (4) using either 
a 28- or a 38-joint count (the 38 JC included MTPs). Of those who reached remission at 1 
year using 28-JC, 26% and 36% had foot synovitis using the Boolean and SDAI definition of 
remission, respectively. Use of the 38-JC lowered remission rate by only 2-3% by the 
Boolean definition. There were several limitations to this study. Importantly, mid- and hind-
foot joints were not assessed (in contrast to our study in which all foot joints were assessed), 
the number of patients who were in remission and still had foot synovitis was small and the 
follow-up was limited to 1 year. Despite these findings, the authors of this study emphasised 
the value of assessing all relevant joints in an individual patient, including the foot joints.  
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We found that shorter remission times are associated with an increase in erosion scores, 
similar to others who have reported that active disease (32)  and disease flares (33) lead to 
greater radiographic progression. Also, joint damage is preceded by increased disease activity 
(34) and therefore use of more stringent DA measures may allow earlier titration of targeted 
therapies in order to reduce radiographic progression. A relatively recent study also reported 
that 25% of patients mainly have radiographic foot progression, as opposed to 50% who 
progress to a similar extent in the hands and feet and 25% who progress mainly in the hands. 
Another longitudinal study (7) reported an increase in erosion scores and the proportion of 
patients having erosions in the feet from 1.3 to 7.9 and from 19% to 60% over 8 years 
respectively.  
 As DAS28 underestimates disease activity mainly in those who exhibit radiographic 
progression in the feet (35), it may underestimate disease activity in 75% of patients. We 
show, for the first time, the relevance of foot synovitis in this context because our transition 
state analysis demonstrates that remission is more unstable in the presence of foot synovitis.  
Consistent with previous studies, baseline SF-36 scores in RA in our study, for all subscales, 
were lower than population norms, correlated with disease activity and improved with 
treatment (11, 12, 36, 37). We also found that foot synovitis in particular, was related to SF-
36 PF scale, even after adjustment for DA, indicating the independent contribution of foot 
synovitis to the SF-36 PF score. This is particularly relevant as many activities of daily living 
such as climbing stairs, walking and recreational activity such as sports are captured in the 
SF-36 score, and may explain why foot synovitis impacts on quality of life. 
Our study is one of only a few studies to analyse outcomes of foot synovitis longitudinally in 
a closely followed treat-to-target inception cohort. To our knowledge, this is also the first 
study to report lack of stable remission and worse functional outcomes in the presence of foot 
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synovitis, enhancing and adding to previous knowledge regarding limitations of DA criteria 
that omit foot joints. This is compounded by the fact that assessment of synovitis of foot 
joints is more difficult to detect clinically than joints of the hand and underscores 
consideration of more sensitive tests such as ultrasound in detection of foot synovitis (38). 
The limitations of our study include the lack of specific measures of foot function and pain 
(such as the Bristol Foot Score). Although this was an open design study, joint examination 
was conducted by a single metrologist, who was not involved in treatment decisions.  
In summary, this study demonstrates that persistent of foot synovitis in common in patients 
with early RA who have otherwise achieved remission on the basis of standard DA measures.  
While the newer measures of DA classified fewer patients with foot synovitis as being in 
remission, they still missed up to 25% of those with active foot synovitis.  Furthermore, those 
with more unstable disease (i.e. those who spent less time in remission) were more likely to 
have active foot synovitis at the time remission was recorded. This has direct consequences: 
shorter remission times are associated with an increase in erosion scores (i.e. damage) and 
foot synovitis is also associated with reduced physical functioning on the SF36, suggesting 
that it increases morbidity. Our findings emphasise the importance of examining the ankle 
and foot as a part of the routine management of patients with RA. Given the impact of foot 
synovitis on stability of remission, radiological progression and independent impact on 
quality of life, decisions should not be made solely on the basis of DA scores that omit foot 
joints. Presence of foot synovitis despite apparent remission should prompt escalation of 
therapy to prevent long-term joint damage and improve functional outcomes.  
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Table 1. Baseline demographic and clinical data (n=266) 
 n (%), mean (SD) or 
median (IQR) 
Age, years, mean (SD)  55         (14) 
Females (%) 190       (71) 
Ever smoked (%) 128       (48) 
BMI, mean (SD) 27.9      (6.2) 
RF positive (%) 161       (60) 
Anti-CCP positive (%) 136       (51) 
Shared Epitope positive (%) 157       (59) 
Symptoms prior to diagnosis, weeks, mean (SD) 23         (32) 
ESR, median (IQR)  29         (31) 
CRP, median (IQR) 10         (24)   
SJC, median (IQR)  
        Total 10         (11) 
        SJC28 7           (8) 
        Ankles & feet 2           (5)     
TJC, median (IQR) 17         (18) 
        Total 17         (18) 
        TJC28 10         (11) 
        Ankles & feet 6           (9) 
Proportion of patients with foot synovitis (TJC and/or SJC) (%) 219       (82) 
DAS28(ESR), mean (SD) 5.43      (1.27) 
DAS28(CRP), mean (SD) 4.99      (1.18) 
SDAI, mean (SD) 31.70    (14.50) 
CDAI, mean (SD) 29.70    (13.80) 
mHAQ, mean (SD)  0.756    (0.549) 
SvH radiographic score, median (IQR)  
          Total score 4           (8) 
          Proportion of patients with erosive disease (%) 64         (27%) 
          Erosion scores in patients with erosive disease (IQR) 1.0         (3.0) 
BMI, body mass index; RF, rheumatoid factor; CCP, cyclic citrullinated peptide; CRP, C-
reactive protein; SJC, swollen joint count; TJC, tender joint count; SJC/TJC 28, SJC/TJC 
using 28 joint count; DAS28, disease activity score calculated using 28 joint count; SDAI, 
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 20 
simplified disease activity index; CDAI, clinical disease activity index; mHAQ, modified 
health assessment questionnaire; SvH, van der Heijde modified Sharp score; JSN, joint space 
narrowing; IQR, inter quartile range. 
 
Table 2. Dynamic correlations between disease activity scores and foot joint counts and 
presence of foot synovitis in patients in remission   
 DC between DA scores and foot joint 
counts (SJC/TJC) 
Foot synovitis in patients in 
remission 
 
 
Foot 
SJC* 
 
Foot 
TJC* 
 
Foot 
SJC + TJC* 
 
All patients in 
remission †¶ 
Patients in 
remission with 
foot synovitis¶ 
DAS28 
(CRP) 
0.24 
(0.10, 0.37) 
0.30 
(0.16, 0.40) 
0.35 
(0.21, 0.43) 
0.47 
(0.11, 0.51) 
0.35 
(0.29, 0.41) 
DAS28 
(ESR) 
0.22 
(0.08, 0.35) 
0.30 
(0.16, 0.42) 
0.34 
(0.20, 0.44) 
0.43 
(0.10, 0.47) 
0.36 
(0.30, 0.42) 
SDAI 
0.32 
(0.12, 0.46) 
0.40 
(0.24, 0.51) 
0.46 
(0.28, 0.55) 
0.28 
(0.05, 0.32) 
0.24 
(0.18, 0.30) 
CDAI 
0.31 
(0.11, 0.46) 
0.40 
(0.24, 0.51) 
0.46 
(0.28, 0.55) 
0.27 
(0.05, 0.31) 
0.25 
(0.19, 0.32) 
 
*  The numbers refer to the dynamic correlation within patients over time (r) (95% CI) 
¶  The numbers here refer to the proportion of patients (95% CI)  
† These include patients in remission regardless of presence or absence of foot synovitis 
DC, dynamic correlation; DA, disease activity;  SJC, swollen joint count; TJC, tender joint 
count; DAS28, disease activity score calculated using 28 joint count; SDAI, simplified 
disease activity index; CDAI, clinical disease activity index 
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Table 3. The effect of foot synovitis on transition intensities from remission to non-
remission and vice versa 
Transition DAS28(CRP)* DAS28(ESR)* SDAI* CDAI* 
Non Remission to 
Remission 
0.68 
(0.42, 1.10) 
0.70 
(0.45, 1.10) 
0.70 
(0.40, 1.24) 
0.68 
(0.39, 1.17) 
Remission to Non-
Remission 
1.47 
(0.84, 2.57) 
1.81 
(1.03, 3.17) 
2.06 
(1.00, 4.26) 
2.08 
(1.03, 4.18) 
Likelihood Ratio 
test p-value 
0.015 0.002 0.0004 0.0002 
*The numbers refer to hazard ratios (95% CI). DA- disease activity;  SJC, swollen joint 
count; TJC, tender joint count; DAS28, disease activity score calculated using 28 joint count; 
SDAI, simplified disease activity index; CDAI, clinical disease activity index 
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Table 4. Regression estimates for disease activity measures and growth rate of erosion scores 
 DAS28(CRP) DAS2(ESR) SDAI CDAI 
 
Estimate SE p Estimate SE P Estimate SE p Estimate SE p 
(Intercept) -2.205 0.267 <0.001 -2.206 0.268 <0.001 -2.216 0.269 <0.001 -2.218 0.269 <0.001 
Age.c 0.044 0.013 0.001 0.043 0.013 0.001 0.044 0.013 0.001 0.044 0.013 0.001 
Anti-CCP 
positive 
0.538 0.192 0.005 0.543 0.191 0.005 0.545 0.193 0.005 0.548 0.193 0.004 
Time 0.434 0.048 <0.001 0.422 0.047 <0.001 0.413 0.041 <0.001 0.406 0.040 <0.001 
Time: DA 
remission.ave 
-0.231 0.085 0.006 -0.210 0.084 0.013 -0.320 0.107 0.003 -0.286 0.105 0.006 
 SE, Standard Error; DAS28, disease activity score calculated using 28 joint count; SDAI, simplified disease activity index; CDAI, clinical 
disease activity index 
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Table 5. Relationship of the foot joint count to SF-36 Physical Function (PF) (Norm 
Based Scale- NBS) 
 Term Estimate 
Standard 
Error p-value 
(Intercept) 43.4 0.6 < 0.001 
Age.c 0.20 0.04 < 0.001 
DAS.CRP.2.6# -4.4 0.4 < 0.001 
sqrt.Foot.SJC.TJC.c* -0.7 0.3 0.025 
# DAS28(CRP) centred around 2.6 as the time varying covariate 
*
 The predictor variable for combined foot (swollen and tender) joint scores. As these scores 
were variable and highly skewed, they were transformed prior to analysis with a square root 
transformation. This transformed variable is “sqrt.Foot.SJC.TJC.c”, also a time varying 
covariate. The intercept is the mean PF NBS for individuals at the mean of the covariates 
(age =55 years, DAS28CRP= 2.6 and SJC+TJC=2) 
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Abstract 
Objectives: To determine whether foot synovitis is associated with adverse radiographic and 
functional outcomes after 3 years in an inception rheumatoid arthritis (RA) cohort receiving 
treat-to-target combination DMARD therapy.  
Methods: Disease activity (DA) was assessed in early RA patients (n=266) using DAS28, 
clinical disease activity index (CDAI) and simplified disease activity index (SDAI). 
Radiographic outcomes were assessed with annual hand and feet radiographs and quality of 
life by SF-36. Prevalence of remission and foot synovitis was calculated using marginal 
binomial generalised estimating equations, transition between remission and non-remission 
states by a multi-state Markov model and changes in radiographic scores by a negative 
binomial mixed regression log-link model. Population matched SF-36 data were analysed by 
mixed-effects linear regression. 
Results: DA scores that omit foot joints were modest in their ability to capture foot synovitis. 
Despite relative stringency of SDAI and CDAI for remission, 25-36% of patients in remission 
had foot synovitis. In patients in remission, foot synovitis predicted transition from remission 
into relapse by up to 2-fold. Sustainability of remission markedly influenced progression of 
erosion scores (p=0.006). After adjusting for DA, foot synovitis was associated with worse 
SF-36 physical functioning (p=0.025). 
Conclusions: DA measures that omit foot joints capture foot synovitis poorly. When used to 
define remission, a substantial proportion have foot synovitis which predicts relapse and 
worse physical function. Foot synovitis influences sustainability of remission which in turn 
markedly influences radiographic progression. Regardless of remission status, persistent foot 
synovitis should prompt therapy escalation to improve long-term outcomes. 
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 Significance and Innovations: 
• Disease activity measures that omit foot joint assessment are modest in their ability to 
capture foot synovitis over time 
• The presence of foot synovitis in patients in remission predicts relapse into non-remission 
and worse radiographic and long-term functional outcomes 
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Rheumatoid arthritis (RA) is a systemic inflammatory disorder that can lead to progressive 
and irreversible joint damage. It is now well-established that intensive target-driven treatment 
with disease modifying anti-rheumatic drugs (DMARDs) produces substantial improvements 
in disease outcomes. These treatment strategies usually rely on a clinic-based composite 
disease activity (DA) measure and it follows that the ability of these measures to capture 
overall DA may influence disease outcomes.  
Various validated composite DA and remission measures have been utilised in published 
series. These include criteria that require a full joint count (e.g. the American College of 
Rheumatology (ACR) Boolean-based criteria) (1), and those employing abbreviated joint 
counts that omit assessment of the ankles and feet. The latter include the 28-joint count DA 
score (DAS28) (2), the Clinical Disease Activity Index (CDAI) and the Simplified Disease 
Activity Index (SDAI) (3). Of these, remission by SDAI has been adopted as an index based 
remission criteria in the recently proposed 2011 ACR/European League Against Rheumatism 
(EULAR) definition of remission (4).  
In an earlier cross-sectional study (5), we found that agreement between remission criteria is 
variable, with the best agreement between the CDAI and SDAI and the poorest with the 
DAS28 and other criteria. This makes comparison of treatments and outcomes among 
inception cohorts using different DA criteria more difficult.  
Furthermore, while abbreviated joint counts may simplify DA indices, we previously 
reported in the same cross-sectional study that DA measures that omit foot joints fail to 
capture synovitis in approximately one-third of patients. This is particularly relevant when it 
is considered that that the feet are the initial site of involvement in early RA in a third or 
more of patients (6), metatarsophalangeal (MTP) joint involvement is present at baseline in 
70% of patients with 40-50% still having painful MTPs after 2 years after diagnosis despite 
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treatment (7) and ~90% report painful ankles or feet at some point during the course of their 
disease (8). Therefore patients with active foot synovitis and well-controlled disease 
elsewhere may be at risk of ongoing damage if treatment decisions are made solely on the 
basis of these abbreviated DA measures (5).  
To explore if persistent foot synovitis should influence treatment, it is necessary to consider 
long-term disease outcomes. Radiographic progression is a robust longitudinal outcome 
measure (9) and foot joints exhibit erosive changes and joint space narrowing (JSN) more 
frequently at baseline and over time in comparison to hand joints in early RA (10). Therefore 
imaging provides a means of assessing whether failure to adjust treatments on the basis of 
persistent foot synovitis translates to different outcomes in the longer term. The 
multidimensional consequences of RA-related foot synovitis on function and health-related 
quality of life are best studied using patient-reported outcome measures. Of these, the health 
assessment questionnaire (HAQ) and the Medical Outcome Study Short-Form 36 (SF-36) are 
probably the best validated in RA. In addition, the SF-36 bodily pain and vitality subscales 
are the most responsive to improvement (11, 12).  
There are limited data regarding the radiographic and functional outcomes of foot synovitis. 
The objectives of this study were to investigate the long term radiographic and functional 
outcomes of foot synovitis at three years in intensively, predominantly conventional DMARD 
treated patients, with the treatment strategy aiming for remission. Our specific aims were (1) 
to investigate dynamic correlations (DCs) between DA measures and foot synovitis, (2) 
analyse the radiographic progression in patients with foot synovitis, and (3), to assess 
functional outcomes of foot synovitis over time.  
PATIENTS AND METHODS 
Participants 
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Our sample comprised consecutive adult (>18 years) patients with early (<12 months) RA 
presenting to the Early Arthritis Clinic (EAC) at the Royal Adelaide Hospital (RAH) between 
2000-2014. Inclusion criteria required participants to be DMARD-naïve and have RA 
according to the 1987 revised ACR (13) and/or the 2010 ACR/EULAR criteria (14). The 
study was approved by the RAH Human Research Ethics Committee.  
Study Protocol 
Details of the EAC cohort, treatment strategy, and results have been published elsewhere (15, 
16). Briefly, all patients commenced treatment with initial triple DMARD therapy 
(methotrexate 10mg weekly, sulfasalazine 500mg twice daily increased to 1g twice daily over 
3 weeks and hydroxychloroquine 200mg twice daily). Treatment was escalated to achieve 
DAS28(ESR) remission by increasing methotrexate to a maximum of 25mg weekly followed 
by addition of leflunomide, other DMARDs or a biologic DMARD according to a pre-
defined algorithm (15). If clinically deemed necessary, patients could have parenteral 
glucocorticoids (typically 120 mg IM depot methyl prednisolone); oral corticosteroids and 
NSAIDs were actively discouraged and if used at study entry, tapered and ceased where 
possible.  
Study evaluations and analyses 
Patients were reviewed every 3-6 weeks. Joint counts (JC) were assessed as tender (53 joints 
and 28 joints; TJC) and swollen (44 joints and 28 joints; SJC) joint counts; foot joints 
included the ankle and joints of the fore-, mid- and hind-foot. Foot synovitis was considered 
to be present if any of the aforementioned foot joints were tender and swollen. A 100 mm 
visual analogue scale was used to assess patient and physician global activity, pain and 
fatigue. Quality of life measures assessed included the modified health assessment 
questionnaire (mHAQ; every visit) and SF-36 (yearly).  
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Composite measures of DA assessed included the DAS28(ESR), DAS28(CRP), CDAI and 
SDAI. The DAS28 was calculated using 4 variables (TJC28, SJC28, general health, and 
ESR/CRP) (17); SDAI and CDAI were calculated using standard formulae (3). For these 
measures, remission was defined as a DAS28-ESR/CRP score of <2.6, CDAI score of ≤ 2.8 
or SDAI score of ≤ 3.3.(3, 18, 19) Patients had yearly radiographic assessments, which were 
scored using the Sharp modified van der Heijde (SvH) method (20) by two independent 
observers (SP, MW). Serial hand and feet radiographs were blinded to identity of participants 
but not to chronological order. 
Statistical analysis 
Statistical analysis was done using the R program for statistics (21). Dynamic (within patient) 
correlations between DA scores and foot TJC and SJC scores were estimated in patients with 
at least three treatment observations over three years’ of follow up (n=217; 810 observations) 
using the R library dynCorr (22), with 95% confidence intervals (CI) estimated by 
bootstrapping. The average prevalence (over all treatment visits) of (1) remission according 
to different DA criteria and (2) foot synovitis (defined as any tender or swollen joints) in 
patients in remission, was estimated using marginal binomial generalised estimating 
equations models in patients with at least one treatment visit (n = 266; 907 observations). 
Transitions between disease remission and non-remission states over time were analysed 
using a multi-state Markov model, using the R library msm (23) in patients with at least two 
treatment visits (n=263; 903 observations), and results are reported as the average length of 
stay (“sojourn time”) in either a remission or non-remission state for the different DA 
remission criteria. A second analysis included foot synovitis as a covariate and results are 
reported as hazard ratios for the effect of foot synovitis on the transition intensity for each 
transition direction. 
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 8 
Radiographic scores (n=238) over  time3 years were analysed using a random intercept, 
marginal exponential growth model to calculate the average annual “growth” rate in scores. 
This was estimated using a negative binomial mixed regression model (log-link), rather than 
a Poisson regression model, because of overdispersion in the radiographic scores. This 
analysis was performed using the R library glmmADMB (24).   
For SF-36 data (n=255), each SF-36 domain scale (0-100) was transformed to a norm-based 
scale (NBS), with a mean of 50 (SD 10), using age and gender matched South Australian 
population data (25), to enable direct comparison between results of each domain. Mixed 
effects linear regression model was applied to analyse associations between disease activity 
and SF-36 scores over 3 years, using the R library nlme (26). To analyse the association of 
foot synovitis and SF-36 scores with foot synovitis as an additional predictor variable, foot 
joint scores were transformed with a square root transformation prior to analysis, because of 
the variable and skewed nature of foot joint counts.  
RESULTS 
Baseline patient characteristics 
The baseline characteristics of patients are presented in Table 1. The mean age was 55, 71% 
were women and 48% were current or past smokers. In this cohort, the prevalence of 
rheumatoid factor (RF), anti-CCP (cyclic citrullinated peptide) and the shared epitope was 
60%, 51% and 59% respectively. Mean baseline DAS28(ESR), SDAI and CDAI were 
consistent with high disease activity; mean mHAQ was 0.756 and mean duration of 
symptoms prior to diagnosis was 23 weeks. Baseline total (median) SvH score was 4; 27% of 
patients had erosive disease at baseline.  
DCs between DA scores and foot joint scores 
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 9 
Dynamic correlations (DCs; these were correlations of foot synovitis with DA within 
patients) were obtained from a minimum of 3 observations (from 6 months to 3 years) per 
patient, during treatment. The DCs within individuals over time are presented in Table 2. All 
DA scores showed a weak to moderate positive correlation with foot swollen joint counts 
(SJC) and tender joint counts (TJC) and the strength of these correlations improved when 
both SJC and TJC were considered. Correlations were comparable for 
DAS28(ESR)/DAS28(CRP) and SDAI/CDAI. Despite the statistical significance of these 
correlations, the DA scores ‘captured’ less than 50% of the variation in foot SJC/TJC counts, 
indicating that assessment of disease activity using these criteria is likely to be insufficient for 
detecting disease flares in the feet. Furthermore, even though the SDAI and CDAI are more 
stringent remission criteria as compared to the DAS28, 24% in SDAI remission and 25% of 
patients in CDAI remission had ongoing foot synovitis (Table 2). 
Sustainability of remission, foot synovitis and prediction of relapse  
As might be expected, we found that in the first 3 years, RA disease activity fluctuates with 
patients transitioning in both directions, between remission and non-remission. When we 
estimated the average length of stay in any one state (the “sojourn time”), we found that the 
sojourn time in remission for SDAI/CDAI was substantially shorter [1.0 years (95% CI 0.6, 
1.4) and 1.0 years (95% CI 0.7, 1.5) respectively] than that for DAS28 based remission [2.0 
years (95% CI 1.35, 2.7)].  
We included foot synovitis as a covariate to determine if the presence of foot synovitis 
affected the probability of transitioning from remission to non-remission, and found that foot 
synovitis significantly influenced the transition intensities (as assessed by the likelihood ratio 
p-value). Patients in DAS28(ESR), SDAI and CDAI remission with foot synovitis were 
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approximately twice as likely to relapse compared to patients in remission without foot 
synovitis (Table 3).  
Radiographic progression 
We analysed progression of both JSN and erosion scores over time. Because of the log-link 
employed in the regression model, the estimated average annual growth (i.e. increase) in 
scores represents the ratio of scores between successive yearly intervals, as opposed to the 
arithmetic difference in scores. The score “growth rate” is therefore strongly influenced by 
factors affecting the baseline score, and this was modelled appropriately in all analyses. 
Age was the most important predictor of baseline JSN, with higher scores occurring among 
older patients (p <0.001; data not shown). For baseline erosion scores, both baseline age and 
anti-CCP status were highly significant predictors (p <0.001). Indeed, results from our 
regression analysis revealed that the estimated ratio of erosion scores, at any given time point, 
for an anti-CCP positive patient as compared to an anti-CCP negative patient was 3.01 (95% 
CI 1.41, 6.84) i.e. a 3 fold difference. For patients with the same baseline age and anti-CCP 
status, the ratio of erosion scores at three years relative to their baseline score was estimated 
as 2.80 (95% CI 2.30, 3.41) i.e. nearly a 3 fold increase over three years. There were no 
significant associations (for either JSN or erosion scores after adjusting for age) with other 
baseline variables including gender, smoking status, duration of symptoms prior to treatment, 
BMI and baseline disease activity scores. 
The effect of Sustained sustained remission markedly reduces on the growth rate of 
erosion scores  
Regression analysis was performed by calculating a time dependant variable (“Time:DA 
remission.ave”; regression estimates are presented in Table 4) to measure whether DA 
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remission was associated with the average annual growth rate of erosion scores. “Time:DA 
remission.ave” reflects the proportion of times a patient was in DA remission over the 4 
treatment time points (6 months, 1 year, 2 years and 3 years).  Age was centred at the mean of 
55 years and the “contrast sum” contrasts [which uses contrast sum coding i.e. (-1,1) instead 
of dummy (0,1) coding] was used to dichotomise anti-CCP status. In this model, the “Time” 
coefficient reflects the (log) growth rate in erosion scores for patients who were never in 
remission; the “Time:DA.remission.ave” coefficient reflects the difference in the (log) 
growth rate for patients with varying success in achieving remission compared to those who 
never achieve remission. We found the coefficient here to be negative, and highly significant 
for each DA score, suggesting that the more remission is sustained, the more pronounced the 
benefit of remission in ameliorating the increase in erosion scores. This is particularly 
relevant, as the transition state analysis of the sojourn time presented earlier has shown that 
remission is more unstable in the presence of foot synovitis. 
Association of DA and foot synovitis with SF-36 scores  is strongly associated with 
scores in each SF-36 domain and foot synovitis is independently associated with 
Physical Functioning domain (PF) 
Analysis of SF-36 scores (based on the baseline and mean score for each patient during 
treatment (years 1, 2 and 3) revealed that although mean SF-36 NBS improved with 
treatment, they were still lower than the general South Australian population scores (data not 
shown). Using regression analysis (Table 5 data not shown), DA during treatment, as 
measured by the DAS28(CRP) was strongly associated with scores in each SF-36 domain, 
most pronounced for Physical Functioning (PF) and General Health (GH). . Baseline age was 
centred around 55 years and predictor variables for the SF-36 domain NBS responses were 
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age and DAS28(CRP). The DAS28(CRP) was centred around 2.6, and as a time-varying 
covariate, included both between patient and within patient effects.  
Although scores were normalised to age and gender matched controls, baseline age was still a 
significant covariate (in contrast to gender) for 7 out of the 8 domains indicating some 
differences between the RA patients and the population controls in the age-score 
relationships. Six of the 8 significant age coefficients were positive, possibly indicating a 
trend for over-correction when normalising RA patients to the population controls. This was 
most pronounced for Physical Functioning (PF) and General Health (GH). As noted in Table 
5, the coefficient for DAS28(CRP) was indicative of a substantial effect. The coefficients 
remained close to 4 units which means a one unit decrease in the DAS28 score (i.e. from 2.6 
to 1.6) is expected to result in an increase in the SF 36 domain NBS of around 4 (and vice 
versa). 
We also analysed the relationship between foot synovitis (foot SJC and foot TJC) scores and 
each domain of the SF-36 during treatment, by the inclusion of an additional covariate (the 
square root of the total synovitis scores). As in the previous analysis, baseline age was 
centred around 55 years, and DAS28(CRP) was centred around 2.6 and the additional 
covariate for foot synovitis scores “sqrt.foot.SJC.TJC.c” was centered around √2. We found 
that the foot joint score is quantitatively related to the SF-36 Physical Functioning (PF), NBS 
scale, even after adjustment for DAS28(CRP) (Table 65). The regression coefficient was 
negative, and highly significant for foot joint score, indicating a lower SF-36 PF in the 
presence of foot synovitis. The other SF-36 domain scores were associated with foot joint 
scores only if the DA score was omitted from the model, indicating that they are likely to be 
secondary associations induced by the correlation between foot joint scores and DA scores. 
DISCUSSION 
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In this cohort of early RA, our study confirms and extends our previous findings concerning 
the underestimation of disease activity using DA measures that omit foot joints. When these 
criteria are used to define remission, a substantial proportion of patients have ongoing foot 
synovitis, which predicts relapse of standard DA measures, radiographic progression and 
worse functional outcomes.  
The goal of treatment in RA is achievement of remission, which is best regarded as a state at 
the very end of a continuum of diminishing disease activity. Given that no one single measure 
is adequate to define remission, composite measures introduced over the years have 
attempted to define cut-point values, with varying levels of stringency. Pinals’ statement in 
1981 that “substantial variation appears to exist in the concept of remission within the group 
of participating rheumatologists” (1, 4) still remains valid. In the current era of biologic 
DMARDs when remission is a realistic goal, it is critical not only to use stringent remission 
criteria, but also recognise their limitations, so that we may achieve the best long-term results 
in individuals. It is in this context that our study assumes particular relevance.  
There are limited longitudinal data on the ability of composite measures that use a limited 
joint count, to “capture” foot synovitis although it is recognised that the SDAI (27) and the 
original DAS (28) have greater stringency than the DAS28. For example, Landewe et al. 
compared DAS with DAS28 remission using paired observations and found DAS remission 
to be more stringent than DAS28 remission, with the discrepancy accounted for by the 
omitted foot joints (28). Kapral et al. (29) compared remission using either a 28 joint count or 
a 32 joint count (this included the ankles and feet as a ‘block’ of 4 joints). Although they 
found that classification of disease activity remained similar whether 28 or 32-joint counts 
were used, DAS28 remission was frequently recorded in the presence of ankle/foot swelling 
(34%) and tenderness (31%). When SDAI remission was recorded, persistent ankle/foot 
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swelling/tenderness occurred in only 8% of such patient visits. In contrast to our cohort, this 
last study had patients with longer disease duration at study entry (8 years mean disease 
duration) and lower baseline disease activity. Our patients had earlier, more active disease 
and this may account for the increase in persistent foot synovitis among our patients in 
remission despite intensive treat-to-target therapy.   
A study from an early RA inception cohort evaluating MTP synovitis found that up to 40% of 
patients in DAS28 remission had at least 1 MTP involved (30). Another study (31) from a 
different early RA cohort evaluated the new ACR/EULAR remission criteria (4) using either 
a 28- or a 38-joint count (the 38 JC included MTPs). Of those who reached remission at 1 
year using 28-JC, 26% and 36% had foot synovitis using the Boolean and SDAI definition of 
remission, respectively. Use of the 38-JC lowered remission rate by only 2-3% by the 
Boolean definition. There were several limitations to this study. Importantly, mid- and hind-
foot joints were not assessed (in contrast to our study in which all foot joints were assessed), 
the number of patients who were in remission and still had foot synovitis was small and the 
follow-up was limited to 1 year. Despite these findings, the authors of this study emphasised 
the value of assessing all relevant joints in an individual patient, including the foot joints.  
We found that shorter remission times are associated with an increase in erosion scores, 
similar to others who have reported that active disease (32)  and disease flares (33) lead to 
greater radiographic progression. Also, joint damage is preceded by increased disease activity 
(34) and therefore use of more stringent DA measures may allow earlier titration of targeted 
therapies in order to reduce radiographic progression. A relatively recent study also reported 
that 25% of patients mainly have radiographic foot progression, as opposed to 50% who 
progress to a similar extent in the hands and feet and 25% who progress mainly in the hands. 
Another longitudinal study (7) reported an increase in erosion scores and the proportion of 
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 15 
patients having erosions in the feet from 1.3 to 7.9 and from 19% to 60% over 8 years 
respectively.  
 As DAS28 underestimates disease activity mainly in those who exhibit radiographic 
progression in the feet (35), it may underestimate disease activity in 75% of patients. We 
show, for the first time, the relevance of foot synovitis in this context because our transition 
state analysis demonstrates that remission is more unstable in the presence of foot synovitis.  
Consistent with previous studies, baseline SF-36 scores in RA in our study, for all subscales, 
were lower than population norms, correlated with disease activity and improved with 
treatment (11, 12, 36, 37). We also found that foot synovitis in particular, was related to SF-
36 PF scale, even after adjustment for DA, indicating the independent contribution of foot 
synovitis to the SF-36 PF score. This is particularly relevant as many activities of daily living 
such as climbing stairs, walking and recreational activity such as sports are captured in the 
SF-36 score, and may explain why foot synovitis impacts on quality of life. 
Our study is one of only a few studies to analyse outcomes of foot synovitis longitudinally in 
a closely followed treat-to-target inception cohort. To our knowledge, this is also the first 
study to report lack of stable remission and worse functional outcomes in the presence of foot 
synovitis, enhancing and adding to previous knowledge regarding limitations of DA criteria 
that omit foot joints. This is compounded by the fact that assessment of synovitis of foot 
joints is more difficult to detect clinically than joints of the hand and underscores 
consideration of more sensitive tests such as ultrasound in detection of foot synovitis (38). 
The limitations of our study include the lack of specific measures of foot function and pain 
(such as the Bristol Foot Score). Although this was an open design study, joint examination 
was conducted by a single metrologist, who was not involved in treatment decisions.  
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In summary, this study demonstrates that persistent of foot synovitis in common in patients 
with early RA who have otherwise achieved remission on the basis of standard DA measures.  
While the newer measures of DA classified fewer patients with foot synovitis as being in 
remission, they still missed up to 25% of those with active foot synovitis.  Furthermore, those 
with more unstable disease (i.e. those who spent less time in remission) were more likely to 
have active foot synovitis at the time remission was recorded. This has direct consequences: 
shorter remission times are associated with an increase in erosion scores (i.e. damage) and 
foot synovitis is also associated with reduced physical functioning on the SF36, suggesting 
that it increases morbidity. Our findings emphasise the importance of examining the ankle 
and foot as a part of the routine management of patients with RA. Given the impact of foot 
synovitis on stability of remission, radiological progression and independent impact on 
quality of life, decisions should not be made solely on the basis of DA scores that omit foot 
joints. Presence of foot synovitis despite apparent remission should prompt escalation of 
therapy to prevent long-term joint damage and improve functional outcomes.  
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Table 1. Baseline demographic and clinical data (n=266) 
 n (%), mean (SD) or 
median (IQR) 
Age, years, mean (SD)  55         (14) 
Females (%) 190       (71) 
Ever smoked (%) 128       (48) 
BMI, mean (SD) 27.9      (6.2) 
RF positive (%) 161       (60) 
Anti-CCP positive (%) 136       (51) 
Shared Epitope positive (%) 157       (59) 
Symptoms prior to diagnosis, weeks, mean (SD) 23         (32) 
ESR, median (IQR)  29         (31) 
CRP, median (IQR) 10         (24)   
SJC, median (IQR)  
        Total 10         (11) 
        SJC28 7           (8) 
        Ankles & feet 2           (5)     
TJC, median (IQR) 17         (18) 
        Total 17         (18) 
        TJC28 10         (11) 
        Ankles & feet 6           (9) 
Proportion of patients with foot synovitis (TJC and/or SJC) (%) 219       (82) 
DAS28(ESR), mean (SD) 5.43      (1.27) 
DAS28(CRP), mean (SD) 4.99      (1.18) 
SDAI, mean (SD) 31.70    (14.50) 
CDAI, mean (SD) 29.70    (13.80) 
mHAQ, mean (SD)  0.756    (0.549) 
SvH radiographic score, median (IQR)  
          Total score 4           (8) 
          Proportion of patients with erosive disease (%) 64         (27%) 
          Erosion scores in patients with erosive disease (IQR) 1.0         (3.0) 
BMI, body mass index; RF, rheumatoid factor; CCP, cyclic citrullinated peptide; CRP, C-
reactive protein; SJC, swollen joint count; TJC, tender joint count; SJC/TJC 28, SJC/TJC 
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using 28 joint count; DAS28, disease activity score calculated using 28 joint count; SDAI, 
simplified disease activity index; CDAI, clinical disease activity index; mHAQ, modified 
health assessment questionnaire; SvH, van der Heijde modified Sharp score; JSN, joint space 
narrowing; IQR, inter quartile range. 
 
Table 2. Dynamic correlations between disease activity scores and foot joint counts and 
presence of foot synovitis in patients in remission   
 DC between DA scores and foot joint 
counts (SJC/TJC) 
Foot synovitis in patients in 
remission 
 
 
Foot 
SJC* 
 
Foot 
TJC* 
 
Foot 
SJC + TJC* 
 
All patients in 
remission †¶ 
Patients in 
remission with 
foot synovitis¶ 
DAS28 
(CRP) 
0.24 
(0.10, 0.37) 
0.30 
(0.16, 0.40) 
0.35 
(0.21, 0.43) 
0.47 
(0.11, 0.51) 
0.35 
(0.29, 0.41) 
DAS28 
(ESR) 
0.22 
(0.08, 0.35) 
0.30 
(0.16, 0.42) 
0.34 
(0.20, 0.44) 
0.43 
(0.10, 0.47) 
0.36 
(0.30, 0.42) 
SDAI 
0.32 
(0.12, 0.46) 
0.40 
(0.24, 0.51) 
0.46 
(0.28, 0.55) 
0.28 
(0.05, 0.32) 
0.24 
(0.18, 0.30) 
CDAI 
0.31 
(0.11, 0.46) 
0.40 
(0.24, 0.51) 
0.46 
(0.28, 0.55) 
0.27 
(0.05, 0.31) 
0.25 
(0.19, 0.32) 
 
*  The numbers refer to the dynamic correlation within patients over time (r) (95% CI) 
¶  The numbers here refer to the proportion of patients (95% CI)  
† These include patients in remission regardless of presence or absence of foot synovitis 
DC, dynamic correlation; DA, disease activity;  SJC, swollen joint count; TJC, tender joint 
count; DAS28, disease activity score calculated using 28 joint count; SDAI, simplified 
disease activity index; CDAI, clinical disease activity index 
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Table 3. The effect of foot synovitis on transition intensities from remission to non-
remission and vice versa 
Transition DAS28(CRP)* DAS28(ESR)* SDAI* CDAI* 
Non Remission to 
Remission 
0.68 
(0.42, 1.10) 
0.70 
(0.45, 1.10) 
0.70 
(0.40, 1.24) 
0.68 
(0.39, 1.17) 
Remission to Non-
Remission 
1.47 
(0.84, 2.57) 
1.81 
(1.03, 3.17) 
2.06 
(1.00, 4.26) 
2.08 
(1.03, 4.18) 
Likelihood Ratio 
test p-value 
0.015 0.002 0.0004 0.0002 
*The numbers refer to hazard ratios (95% CI). DA- disease activity;  SJC, swollen joint 
count; TJC, tender joint count; DAS28, disease activity score calculated using 28 joint count; 
SDAI, simplified disease activity index; CDAI, clinical disease activity index 
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23 
Table 4. Regression estimates for disease activity measures and growth rate of erosion scores 
 DAS28(CRP) DAS2(ESR) SDAI CDAI 
 
Estimate SE p Estimate SE P Estimate SE p Estimate SE p 
(Intercept) -2.205 0.267 <0.001 -2.206 0.268 <0.001 -2.216 0.269 <0.001 -2.218 0.269 <0.001 
Age.c 0.044 0.013 0.001 0.043 0.013 0.001 0.044 0.013 0.001 0.044 0.013 0.001 
Anti-CCP 
positive 
0.538 0.192 0.005 0.543 0.191 0.005 0.545 0.193 0.005 0.548 0.193 0.004 
Time 0.434 0.048 <0.001 0.422 0.047 <0.001 0.413 0.041 <0.001 0.406 0.040 <0.001 
Time: DA 
remission.ave 
-0.231 0.085 0.006 -0.210 0.084 0.013 -0.320 0.107 0.003 -0.286 0.105 0.006 
 SE, Standard Error; DAS28, disease activity score calculated using 28 joint count; SDAI, simplified disease activity index; CDAI, clinical 
disease activity index 
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Table 5. Associations of SF-36 domains with disease activity. 
SF-36 Domain 
Regression Coefficients 
Intercept Age.c DAS28.CRP.2.6 
E SE p-value E SE p-value E SE p-value 
Physical Functioning 43.7 0.6 < 0.001 0.21 0.04 < 0.001 -4.9 0.4 < 0.001 
Role Physical  45.7 0.5 < 0.001 0.08 0.03 0.005 -3.8 0.2 < 0.001 
Bodily Pain  48.0 0.4 < 0.001 0.08 0.03 0.002 -4.4 0.3 < 0.001 
General Health  45.2 0.5 < 0.001 0.24 0.03 < 0.001 -3.4 0.3 < 0.001 
Vitality  47.0 0.5 < 0.001 0.07 0.03 0.023 -3.5 0.3 < 0.001 
Social Functioning  46.3 0.6 < 0.001 -0.10 0.04 0.007 -3.0 0.3 < 0.001 
Role Emotional  47.0 0.5 < 0.001 0.07 0.03 0.023 -3.5 0.3 < 0.001 
Mental Health 38.8 0.6 < 0.001 -0.02 0.04 0.59 -4.0 0.4 < 0.001 
E- Estimate, SE- Standard Error 
Table 65. Relationship of the foot joint count to SF-36 Physical Function (PF) (Norm 
Based Scale- NBS) 
 Term Estimate 
Standard 
Error p-value 
(Intercept) 43.4 0.6 < 0.001 
Age.c 0.20 0.04 < 0.001 
DAS.CRP.2.6# -4.4 0.4 < 0.001 
sqrt.Foot.SJC.TJC.c* -0.7 0.3 0.025 
# DAS28(CRP) centred around 2.6 as the time varying covariate 
*
 The predictor variable for combined foot (swollen and tender) joint scores. As these scores 
were variable and highly skewed, they were transformed prior to analysis with a square root 
transformation. This transformed variable is “sqrt.Foot.SJC.TJC.c”, also a time varying 
covariate. The intercept is the mean PF NBS for individuals at the mean of the covariates 
(age =55 years, DAS28CRP= 2.6 and SJC+TJC=2) 
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